MarketBeat
07 Aug 2026, 09:05 UTC · 1h ago
Profound Medical Q2 Earnings Call Highlights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
07 Aug 2026, 09:05 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
CMS' proposed 2027 hospital outpatient rule would increase TULSA payment by 14.9% to $15,494, exceeding payments for HIFU, Aquablation, and robotic radical prostatectomy. — Higher reimbursement rates relative to competitors directly increase the financial attractiveness of the procedure for providers, driving adoption.
+0.80The company's qualified sales pipeline for TULSA-PRO and Sonalleve is approximately CAD 70 million. — A strong, quantified pipeline provides visibility into future revenue growth and validates market demand.
+0.60The company reported Q2 revenue of CAD 2.5 million, significantly below the CAD 5.6 million it would have been without a CAD 3.1 million shipment timing delay. — While the delay is attributed to logistics rather than demand, the reported miss creates short-term volatility and highlights operational friction.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Profound Medical maintained its full-year 2026 revenue guidance of approximately CAD 25 million, representing 56% growth from 2025. — Maintaining guidance despite the Q2 shipment delay signals management's confidence in recovering the revenue in Q3.
+0.30The CAPTAIN trial data showed TULSA had statistically superior preservation of urinary continence and erectile function at six months compared to robotic radical prostatectomy. — Superior clinical outcomes provide the medical evidence necessary to shift patient and surgeon preference away from the gold standard.
+0.30Which stocks this story touches
Despite a shipment timing issue affecting Q2 revenue, the company showed gross margin expansion, reduced net losses, and strong clinical trial data.
Mentioned only as a source of covered lives for a third-party product with no material impact on its own business.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Seeking Alpha
1h ago
